Latest UCB Inc. Stories

ATLANTA, May 3 /PRNewswire/ -- UCB and the Inflammatory Bowel Disease Working Group (IBDWG) today announced the five recipients of the 2010 Research Awards in Inflammatory Bowel Disease (IBD) for Gastroenterology (GI) Fellows, each of whom will receive a one-year $40,000 research grant for their original clinical or basic research. The recipients were selected by the IBDWG Steering Committee and the awards were funded by a grant from UCB, Inc. A reception honoring the recipients will be...

ATLANTA, April 14 /PRNewswire/ -- Evidence of Neupro® (Rotigotine Transdermal System) improving motor as well as non-motor symptoms of Parkinson's disease was presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada. "The new data reported this week showed that treatment with rotigotine controlled early morning motor function and improved non-motor symptoms, as judged by the validated non-motor scale, in patients with Parkinson's disease and these effects...

ATLANTA, April 13 /PRNewswire/ -- New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome (RLS) using rotigotine achieved sustained improvements in symptoms over 5 years of treatment. "Many people with RLS will have spent months or years trying to get a diagnosis and find a treatment that can help them. So these 5-year results provide additional evidence that, once they start using...

ATLANTA, April 9 /PRNewswire/ -- The antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) will be the subject of numerous studies and analyses at the 62nd annual American Academy of Neurology (AAN) meeting, taking place at the Metro Toronto Convention Centre in Toronto from April 10-17. To view the multimedia assets associated with this release, please click: http://www.prnewswire.com/mnr/vimpat/34012/ "The breadth and depth of Vimpat data being presented at AAN suggests that the...

ATLANTA, March 11 /PRNewswire/ -- UCB today announced that the antiepileptic drug (AED) Vimpat® (lacosamide) (C-V) demonstrated significantly fewer partial-onset seizures versus placebo in adults living with epilepsy, according to a Phase III clinical study published online in Epilepsia. This study was one of three that supported the approval of Vimpat by the U.S. Food and Drug Administration (FDA) in 2008 for use as an add-on therapy for the treatment of partial-onset seizures in people...

ATLANTA, Nov. 3 /PRNewswire/ -- UCB, an active participant in the epilepsy community for more than a decade, is proudly launching a variety of patient-centered initiatives in honor of Epilepsy Awareness Month in November. These programs are the culmination of years of experience in the epilepsy community and seek to empower patients, improve epilepsy care, and raise awareness about the condition. "At UCB, our goal has always been to make a meaningful and lasting difference in the epilepsy...

ATLANTA and BRIDGEWATER, N.J. Sept. 8 /PRNewswire/ -- From cubbies and carpets to class pets and pollen, as parents prepare for this year's back to school they should also prepare for the upcoming fall allergy season. To help children with nasal allergies ease into the new school year, the My Xperts(TM) program, created by UCB and sanofi-aventis U.S. LLC., is offering new tips from a team of indoor and outdoor nasal allergy experts to help parents prepare for fall allergy season in and out...

Cimzia(R) shows duration of response up to week 26 in moderate to severe Crohn's patients who failed the intravenous infusion treatment infliximab. CHICAGO, June 1 /PRNewswire/ -- New data from the WELCOME study presented by UCB at the Digestive Disease Week meeting demonstrate that Cimzia(R) (certolizumab pegol) provides sustained symptom improvement with stable dosing through week 26 for adult patients suffering from moderate to severe Crohn's disease (CD) who are intolerant or no longer...

CHICAGO, June 1 /PRNewswire/ -- UCB, Inc. and the Crohn's Disease Working Group (CDWG) today announced the four recipients of the 2009 Research Awards in Inflammatory Bowel Disease (IBD) for Gastroenterology (GI) Fellows, who each will receive a one-year research grant for their original clinical or basic research, totaling $175,000 for all four grants. The recipients were selected by the CDWG Steering Committee and the awards were funded by a grant from UCB. A reception honoring the...

- New antiepileptic drug with novel mechanism of action helps address critical unmet medical need for many people living with uncontrolled epilepsy - Vimpat(R) offers hope to people with epilepsy who still have uncontrolled partial onset seizures with current treatment ATLANTA, May 26 /PRNewswire/ -- press release, regulated information - UCB today announced that Vimpat(R) (lacosamide) C-V, a new antiepileptic drug (AED) is available in the U.S. as an add-on therapy for the treatment of...